Ireland
--:--IST
Clinical Trials in the EU / 2025-521711-39-00
Authorised, recruiting Phase III

A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

2025-521711-39-00 · tracked via the Priya Life Science EU tracker
Sponsor type
Pharmaceutical company
Therapeutic area
Nervous System Diseases
Decision date
03/11/2025
Enrollment target
49
Sites
Czechia, Italy, France, Bulgaria

Condition studied

Lewy body Dementia psychosis (LBDP)

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

Treatment-emergent adverse events (TEAEs)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521711-39-00 on CTIS ↗ ← All trials in the EU